Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients
David E. Leaf, … , Edy Y. Kim, Sushrut S. Waikar
David E. Leaf, … , Edy Y. Kim, Sushrut S. Waikar
Published September 9, 2025
Citation Information: JCI Insight. 2025;10(20):e193523. https://doi.org/10.1172/jci.insight.193523.
View: Text | PDF
Clinical Research and Public Health Endocrinology Immunology Nephrology

Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients

  • Text
  • PDF
Abstract

BACKGROUND Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.METHODS We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high risk of moderate to severe acute kidney injury (AKI). The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure. Secondary endpoints included new or progressive AKI and a composite of KRT or death. Hypercalcemia was the key safety endpoint. We also performed RNA-Seq on circulating CD14+ monocytes collected immediately prior to randomization and 2 days later.RESULTS The global rank score for the primary endpoint was similar among calcifediol- (n = 51) versus placebo- (n = 49) treated patients (P = 0.85) and for calcitriol (n = 50) versus placebo-treated patients (P = 0.58). Secondary endpoints also occurred at similar rates across groups. Hypercalcemia occurred in 1 patient in the calcifediol group (1.7%), 1 patient in the calcitriol group (2.0%), and no patients in the placebo group. Compared with placebo, calcitriol upregulated more individual genes and pathways in circulating monocytes than did calcifediol, including pathways involving IFN-α, IFN-γ, oxidative phosphorylation, DNA repair, and heme metabolism.CONCLUSION Treatment with calcifediol or calcitriol in critically ill adults upregulated multiple genes and pathways involving immunomodulation, DNA repair, and heme metabolism, but it did not attenuate AKI.TRIAL REGISTRATION ClinicalTrials.gov (NCT02962102)FUNDING NIH/NIDDK grant K23DK106448 (to DEL) and NIH/NHLBI grant R01HL16687 (to EYK).

Authors

David E. Leaf, Tushar Shenoy, Kevin Zinchuk, Shruti Gupta, Julie-Alexia Dias, Daniel Sanchez-Almanzar, Adit A. Ginde, Humra Athar, Changde Cheng, Tomoyoshi Tamura, Edy Y. Kim, Sushrut S. Waikar

×

Figure 1

Overview of vitamin D metabolism.

Options: View larger image (or click on image) Download as PowerPoint
Overview of vitamin D metabolism.
Vitamin D is derived from dietary sour...
Vitamin D is derived from dietary sources and sunlight-induced cutaneous synthesis, and is converted to 25D in the liver. 25D, a partially activated vitamin D metabolite, is converted to its fully activated form, 1,25D, in the kidneys, immune cells, and other tissues by the cytochrome P450 enzyme, CYP27B1 (1-α hydroxylase). 1,25D binds to the cytoplasmic VDR, which is expressed nearly ubiquitously. The 1,25D-VDR complex translocates into the nucleus, where it binds to DNA sequence elements in vitamin D–responsive genes, ultimately influencing the expression of over 200 target genes. These include genes that encode antiinflammatory proteins, such as HO-1 and IL-10, as well as genes that upregulate production of Tregs, each of which attenuates acute organ injury in animal models. 25D can also bind to the VDR (dashed arrow). Its affinity for the VDR is several hundred–fold lower than that of 1,25D, but 25D circulates at ~1,000-fold higher concentrations than 1,25D. 1,25D, 1,25-dihydroxyvitamin D; 25D, 25-hydroxyvitamin D; HO-1, heme oxygenase-1; VDR, vitamin D receptor.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts